Tags

Type your tag names separated by a space and hit enter

Placental dysfunction in Suramin-treated rats: impact of maternal diabetes and effects of antioxidative treatment.
J Soc Gynecol Investig. 2005 Apr; 12(3):174-84.JS

Abstract

OBJECTIVE

The aim of the present study was to evaluate a rat model of placental dysfunction/preeclampsia in pregnancies complicated by maternal diabetes. A second objective was to evaluate the effects of vitamin E treatment in this model.

METHODS

Normal and streptozotocin-induced diabetic rats of two different strains (U and H) were given intraperitoneal (IP) injections of the angiogenesis inhibitor Suramin (Sigma Chemical Co, St Louis, MO) or saline in early pregnancy, and fed standard or vitamin E-enriched food. The outcome of pregnancy was evaluated on gestational day 20.

RESULTS

In both rat strains Suramin caused fetal growth retardation, decreased placental blood flow, and increased placental concentration of the isoprostane 8-iso-PGF(2alpha). In the U rats Suramin also caused increased fetal resorption rate, increased maternal blood pressure, decreased renal blood flow, and diminished maternal growth. Diabetes caused severe maternal and fetal growth retardation, increased resorption rate, and increased placental 8-iso-PGF(2alpha) concentration independent of Suramin administration. The maternal and fetal effects of Suramin and diabetes were more pronounced in the U strain than in the H strain. Vitamin E treatment improved the status of Suramin-injected diabetic rats: in U rats the blood pressure increase was normalized; and in both U and H rats the decreased placental blood flow was marginally enhanced, and the increase in placental 8-iso-PGF(2alpha) was partly normalized by vitamin E.

CONCLUSION

Suramin injections to pregnant rats cause a state of placental insufficiency, which in U rats resembles human preeclampsia. The induction of this condition is at least partly mediated by oxidative stress, and antagonized by antioxidative treatment. Maternal diabetes involves increased oxidative stress, and causes both maternal and fetal morbidity, which are only marginally affected by additional Suramin treatment.

Authors+Show Affiliations

Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15784502

Citation

Nash, Peppi, et al. "Placental Dysfunction in Suramin-treated Rats: Impact of Maternal Diabetes and Effects of Antioxidative Treatment." Journal of the Society for Gynecologic Investigation, vol. 12, no. 3, 2005, pp. 174-84.
Nash P, Olovsson M, Eriksson UJ. Placental dysfunction in Suramin-treated rats: impact of maternal diabetes and effects of antioxidative treatment. J Soc Gynecol Investig. 2005;12(3):174-84.
Nash, P., Olovsson, M., & Eriksson, U. J. (2005). Placental dysfunction in Suramin-treated rats: impact of maternal diabetes and effects of antioxidative treatment. Journal of the Society for Gynecologic Investigation, 12(3), 174-84.
Nash P, Olovsson M, Eriksson UJ. Placental Dysfunction in Suramin-treated Rats: Impact of Maternal Diabetes and Effects of Antioxidative Treatment. J Soc Gynecol Investig. 2005;12(3):174-84. PubMed PMID: 15784502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Placental dysfunction in Suramin-treated rats: impact of maternal diabetes and effects of antioxidative treatment. AU - Nash,Peppi, AU - Olovsson,Matts, AU - Eriksson,Ulf J, PY - 2005/3/24/pubmed PY - 2005/8/6/medline PY - 2005/3/24/entrez SP - 174 EP - 84 JF - Journal of the Society for Gynecologic Investigation JO - J Soc Gynecol Investig VL - 12 IS - 3 N2 - OBJECTIVE: The aim of the present study was to evaluate a rat model of placental dysfunction/preeclampsia in pregnancies complicated by maternal diabetes. A second objective was to evaluate the effects of vitamin E treatment in this model. METHODS: Normal and streptozotocin-induced diabetic rats of two different strains (U and H) were given intraperitoneal (IP) injections of the angiogenesis inhibitor Suramin (Sigma Chemical Co, St Louis, MO) or saline in early pregnancy, and fed standard or vitamin E-enriched food. The outcome of pregnancy was evaluated on gestational day 20. RESULTS: In both rat strains Suramin caused fetal growth retardation, decreased placental blood flow, and increased placental concentration of the isoprostane 8-iso-PGF(2alpha). In the U rats Suramin also caused increased fetal resorption rate, increased maternal blood pressure, decreased renal blood flow, and diminished maternal growth. Diabetes caused severe maternal and fetal growth retardation, increased resorption rate, and increased placental 8-iso-PGF(2alpha) concentration independent of Suramin administration. The maternal and fetal effects of Suramin and diabetes were more pronounced in the U strain than in the H strain. Vitamin E treatment improved the status of Suramin-injected diabetic rats: in U rats the blood pressure increase was normalized; and in both U and H rats the decreased placental blood flow was marginally enhanced, and the increase in placental 8-iso-PGF(2alpha) was partly normalized by vitamin E. CONCLUSION: Suramin injections to pregnant rats cause a state of placental insufficiency, which in U rats resembles human preeclampsia. The induction of this condition is at least partly mediated by oxidative stress, and antagonized by antioxidative treatment. Maternal diabetes involves increased oxidative stress, and causes both maternal and fetal morbidity, which are only marginally affected by additional Suramin treatment. SN - 1071-5576 UR - https://www.unboundmedicine.com/medline/citation/15784502/Placental_dysfunction_in_Suramin_treated_rats:_impact_of_maternal_diabetes_and_effects_of_antioxidative_treatment_ L2 - https://medlineplus.gov/diabetesandpregnancy.html DB - PRIME DP - Unbound Medicine ER -